Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free SRNE Stock Alerts

Sorrento Therapeutics (SRNE) Competitors

Sorrento Therapeutics logo
$0.0004 0.00 (0.00%)
As of 03:31 PM Eastern
Compare

SRNE vs. PRFX, ATHX, CERO, BPTSY, and CDT

Should you buy Sorrento Therapeutics stock or one of its competitors? Sorrento Therapeutics's main competitors and comparable companies include PainReform (PRFX), Athersys (ATHX), CERo Therapeutics (CERO), Biophytis (BPTSY), and CDT Equity (CDT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sorrento Therapeutics compare to PainReform?

PainReform (NASDAQ:PRFX) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Company Net Margins Return on Equity Return on Assets
PainReformN/A N/A N/A
Sorrento Therapeutics N/A N/A N/A

PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market.

In the previous week, PainReform had 5 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 5 mentions for PainReform and 0 mentions for Sorrento Therapeutics. PainReform's average media sentiment score of 0.85 beat Sorrento Therapeutics' score of 0.00 indicating that PainReform is being referred to more favorably in the media.

Company Overall Sentiment
PainReform Positive
Sorrento Therapeutics Neutral

PainReform has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PainReform$20K37.41-$5.02M-$736.66N/A
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.17N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PainReform
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

37.3% of PainReform shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

PainReform beats Sorrento Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Athersys?

Sorrento Therapeutics (NASDAQ:SRNE) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Athersys Neutral

Athersys has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.17N/A
Athersys$146K0.00-$72.53M-$2.03N/A

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Athersys N/A N/A -223.03%

Sorrento Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

Summary

Sorrento Therapeutics beats Athersys on 5 of the 8 factors compared between the two stocks.

How does Sorrento Therapeutics compare to CERo Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

CERo Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$9.84N/A
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.17N/A

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
Sorrento Therapeutics N/A N/A N/A

CERo Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 288,361.54%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe CERo Therapeutics is more favorable than Sorrento Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Sorrento Therapeutics Neutral

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

CERo Therapeutics beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Biophytis?

Sorrento Therapeutics (NASDAQ:SRNE) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Biophytis Neutral

Biophytis has lower revenue, but higher earnings than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.17N/A
BiophytisN/AN/A-$18.43MN/AN/A

Sorrento Therapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market.

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Biophytis N/A N/A N/A

Summary

Biophytis beats Sorrento Therapeutics on 4 of the 5 factors compared between the two stocks.

How does Sorrento Therapeutics compare to CDT Equity?

Sorrento Therapeutics (NASDAQ:SRNE) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

CDT Equity has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.17N/A
CDT EquityN/AN/A-$39.22M-$3.35 thousandN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, CDT Equity had 4 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Sorrento Therapeutics. CDT Equity's average media sentiment score of 0.46 beat Sorrento Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company Overall Sentiment
Sorrento Therapeutics Neutral
CDT Equity Neutral

Sorrento Therapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Sorrento Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
CDT Equity N/A -72.25%-55.44%

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 7.3% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CDT Equity beats Sorrento Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRNE vs. The Competition

Export
MetricSorrento TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$221K$12.35B$7.12B$12.83B
Dividend YieldN/A2.62%2.56%10.57%
P/E Ratio0.00797.19273.2625.18
Price / Sales0.00758.98631.6187.80
Price / CashN/A90.5577.3351.83
Price / BookN/A10.3910.336.20
Net Income-$572.84M$2.82B$3.49B$358.38M
7 Day PerformanceN/A-3.47%-3.27%-2.35%
1 Month PerformanceN/A1.32%-0.24%-2.61%
1 Year PerformanceN/A2.81%17.32%8.07%

Sorrento Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-80.0%$221K$60.32MN/A800
PRFX
PainReform
0.8871 of 5 stars		$0.95
-2.4%		N/A-86.4%$841K$31KN/A4
ATHX
Athersys
N/AN/AN/AN/A$833K$146KN/A24
CERO
CERo Therapeutics
0.9511 of 5 stars		$0.01
+9.1%		$30.00
+249,900.0%		-99.8%$788KN/AN/A8
BPTSY
Biophytis
N/A$0.25
flat		N/AN/A$586KN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 9/11/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel